Paper Details

  1. Home
  2. Paper Details

[Antiangiogenics: new therapeutic standards in metastatic kidney cancer].

Author: BensalahK, CornuJ-N, OudardS, PatardJ-J, RouprêtM

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This review discusses the evolving treatment landscape for metastatic renal cell carcinoma, with the introduction of antiangiogenic and m-TOR inhibitor therapies since 2004. While these therapies improve progression-free survival and overall survival, their side effects are not negligible.
Paper Details　
Original Abstract of the Article :
Since 2004, the treatment of metastatic renal cell carcinoma is in deep mutation. Before, the Management was mostly relying on the use of cytokines in association with radical nephrectomy. From 2004, studies of new antiangiogenic molecules, acting on the pVHL-HIF way, VEGF, PDGF or tyrosine-kinase r...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1166-7087(08)73665-0

データ提供：米国国立医学図書館（NLM）

[Antiangiogenics: new therapeutic standards in metastatic kidney cancer]

This article provides a compelling overview of the transformative role of antiangiogenic agents in the treatment of metastatic renal cell carcinoma (mRCC). The introduction of these agents, targeting the pathways involved in tumor blood vessel formation, has significantly impacted the management of mRCC, improving progression-free survival and offering hope for better outcomes. The article explores various antiangiogenic molecules, including sunitinib, sorafenib, temsirolimus, and bevacizumab, and their respective roles and side effects.

Antiangiogenics: A new era in kidney cancer treatment

The article highlights the significant advancement in mRCC treatment brought about by antiangiogenic agents. These agents have proven to be effective in improving progression-free survival, offering patients with mRCC a more favorable prognosis.

Navigating the desert of cancer treatment

As a wise camel, I know that navigating the desert of cancer treatment can be an arduous journey. This article offers a beacon of hope for patients with mRCC, showcasing the remarkable progress in treatment options. It is crucial to consult with an oncologist to determine the most appropriate treatment plan, taking into account individual needs and potential risks and benefits.

Dr.Camel's Conclusion

The article provides a comprehensive overview of the advancements in antiangiogenic therapy for mRCC, highlighting the significant impact of these agents on patient outcomes. The future of mRCC treatment promises even greater breakthroughs as research continues to explore novel strategies and optimize existing therapies.

Date :
  1. Date Completed 2009-01-15
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

18706374

DOI: Digital Object Identifier

10.1016/S1166-7087(08)73665-0

Related Literature

Article Analysis
・Side Effects of temsirolimus
SNS
PICO Info
in preparation
Languages

French

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.